| LUMOXITIDetailsLeukemia, Cancer |
Approved |
| Monalizumab + durvalumab + oleclumabDetailsNon-small cell lung carcinoma, Cancer, Solid tumor/s |
Phase 3 |
| IPH6101 / SAR443579DetailsCancer, Relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia |
Phase 2 |
| IPH5201DetailsLung cancer, Cancer, Non-small cell lung carcinoma |
Phase 2 |
| Monalizumab (anti-NKG2A)DetailsSolid tumor/s, Cancer |
Phase 2 |
| Lacutamab (IPH4102) + GEMOXDetailsCancer, Lymphoma, Peripheral T cell cancer |
Phase 2 |
| Lacutamab (IPH4102)DetailsLymphoma, Sezary syndrome, Cancer |
Phase 2 |
| Lacutamab (IPH4102)DetailsLymphoma, Cancer, Mycosis fungoides |
Phase 2 |
| Avdoralimab (IPH5401)DetailsCOVID-19, Infectious disease |
Phase 2 |
| IPH6401 / SAR’514DetailsCancer, relapsed or refractory light chain amyloidosis, Multiple myeloma, Post-stroke recovery |
Phase 1/2 |
| IPH6501DetailsCancer, Non-Hodgkin lymphoma |
Phase 1/2 |
| Lacutamab (IPH4102)DetailsCancer, Lymphoma, Peripheral T cell cancer |
Phase 1b |
| IPH5301 (anti-CD73)DetailsCancer, Solid tumor/s |
Phase 1 |
| IPH4502DetailsCancer, Solid tumor/s |
Phase 1 |
| Avdoralimab (IPH5401)DetailsBullous pemphigoid , Skin disease/disorder |
Failed |
| Monalizumab (anti-NKG2A)DetailsHead and neck cancer, Head and neck squamous cell carcinoma, Cancer |
Failed |
